Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

73.46
Delayed Data
As of 3:56pm ET
 +0.46 / +0.63%
Today’s Change
51.82
Today|||52-Week Range
75.12
+6.79%
Year-to-Date
BMY Regular Dividend: BMY began trading ex-dividend on 06/29/16. A $0.38 dividend will be paid to shareholders of record as of 07/01/16.
Horizon (HZNP) Stock Up on Ravicti Label Expansion Filing
10:50am / Zacks.com - Paid Partner Content
Roche's Multiple Sclerosis Drug Under Review by FDA, EMA
Jun 29 / Zacks.com - Paid Partner Content
AbbVie, J&J's Imbruvica Gets Breakthrough Therapy Status
10:18am / Zacks.com - Paid Partner Content
How Pfizer, Merck May Feel Long-term Pinch From Brexit
Jun 29 / TheStreet.com - Paid Partner Content
Galena (GALE) Stock Falls on Discontinuation of NeuVax Study
8:50am / Zacks.com - Paid Partner Content
Esperion (ESPR) Offers Updates on LDL-Lowering Candidate
Jun 29 / Zacks.com - Paid Partner Content
These Large Pharmaceutical Stocks Should be on your Radar
Jun 29 / Zacks.com - Paid Partner Content
Infinity Regains Duvelisib Rights, Announces Restructuring
Jun 29 / Zacks.com - Paid Partner Content
McKesson's IT Business to Merge with Change Healthcare
Jun 29 / Zacks.com - Paid Partner Content
Endo's Stock Gains on Vasostrict's New Patent Approval
Jun 29 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close73.00
Today’s open73.10
Day’s range72.71 - 73.75
Volume3,677,516
Average volume (3 months)6,099,286
Market cap$121.9B
Dividend yield2.07%
Data as of 3:56pm ET, 06/30/2016

Growth & Valuation

Earnings growth (last year)-22.50%
Earnings growth (this year)+27.06%
Earnings growth (next 5 years)+21.20%
Revenue growth (last year)+4.29%
P/E ratio78.4
Price/Sales6.97
Price/Book8.50

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.57+1.38%
NVONovo Nordisk+0.71+1.34%
GSKGlaxoSmithKline+0.84+1.98%
ABBVAbbVie-0.05-0.07%
Data as of 3:56pm ET, 06/30/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.66
Annual revenue (last year)$16.6B
Annual profit (last year)$1.6B
Net profit margin9.45%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs